The Food and Drug Administration on Tuesday will issue draft guidance for how companies developing cell and gene therapies ...
With the FDA expecting to approve 10–20 Cell and Gene Therapies (CGTs) annually by 2025, it is evident that the field will continue to hold immense commercial and medical opportunities. To harness ...
A key claim by the company MedTherapy is a major reduction in production timelines. While gene therapies typically take weeks ...
This story is part of a series on the current progression in Regenerative Medicine. In 1999, I defined regenerative medicine as the collection of interventions that restore tissues and organs damaged ...
In this webinar, Gonçalo Regalo discusses how raw materials, media composition, and process design influence scalable cell therapy manufacturing.
Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine One of the more exciting opportunities in medical ...
Leaders from the world of cell and gene therapy, including molecular geneticists, immunotherapists, physicians, nonprofit directors, and patient advocates, shared their personal stories and policy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results